Indivior Pharmaceuticals
INDV
95 hedge funds and large institutions have $3.4B invested in Indivior Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 6 closing their positions.
3,100% more call options, than puts
Call options by funds: $64K | Put options by funds: $2K
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
229% more capital invested
Capital invested by funds: $1.04B → $3.4B (+$2.37B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more funds holding
Funds holding: 76 → 95 (+19)
2.61% more ownership
Funds ownership: 46.94% → 49.55% (+2.6%)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$63M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$32.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.1M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$14.4M |
| 5 |
JP Morgan Chase
New York
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$42M |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$31.8M |
| 3 |
Barclays
London,
United Kingdom
|
-$19.1M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$16M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
-$10.5M |
INDV Hedge Fund Activity: Q1 2024 in Review
95 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q1 2024, worth a combined $3.4B — up 229% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new INDV positions and 6 closed out — a net gain of 19 holders — while 28 added to existing stakes and 26 trimmed.
The largest buyer was Oaktree Capital Management, opening a new position worth an estimated $63M. The largest seller was Scopia Capital Management, cutting an estimated $42M.
- 95 institutional investors held Indivior Pharmaceuticals (INDV) as of Q1 2024, up from 76 in Q4 2023.
- Funds reported $3.4B of Indivior Pharmaceuticals stock for Q1 2024, up 229% quarter-over-quarter.
- 25 funds opened new Indivior Pharmaceuticals positions in Q1 2024 and 6 closed out, a net change of +19 holders.
- The largest Indivior Pharmaceuticals buyer in Q1 2024 was Oaktree Capital Management, an estimated $63M added.
- The largest Indivior Pharmaceuticals seller in Q1 2024 was Scopia Capital Management, an estimated $42M sold.
Based on aggregated 13F filings for Q1 2024.